160 related articles for article (PubMed ID: 34702753)
21. Impact of anti-T-cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplant recipients.
Orcurto A; Pascual M; Hoschler K; Aubert V; Meylan P; Manuel O
Transplantation; 2012 Sep; 94(6):630-6. PubMed ID: 22895612
[TBL] [Abstract][Full Text] [Related]
22. Vitamin E, vitamin A, and zinc status are not related to serologic response to influenza vaccine in older adults: an observational prospective cohort study.
Sundaram ME; Meydani SN; Vandermause M; Shay DK; Coleman LA
Nutr Res; 2014 Feb; 34(2):149-54. PubMed ID: 24461316
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine.
Seo YB; Lee J; Song JY; Choi HJ; Cheong HJ; Kim WJ
Hum Vaccin Immunother; 2016; 12(2):478-84. PubMed ID: 26431466
[TBL] [Abstract][Full Text] [Related]
24. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Le Corre N; Thibault F; Pouteil Noble C; Meiffrédy V; Daoud S; Cahen R; Charreau I; Bottigioli D; Dollinger C; Aboulker JP; Autran B; Morelon E; Barrou B
Vaccine; 2012 Dec; 30(52):7522-8. PubMed ID: 23103195
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy.
Shirai S; Hara M; Sakata Y; Tsuruoka N; Yamamoto K; Shimoda R; Gomi Y; Yoshii H; Fujimoto K; Iwakiri R
Inflamm Bowel Dis; 2018 Apr; 24(5):1082-1091. PubMed ID: 29538682
[TBL] [Abstract][Full Text] [Related]
26. Comparison of hemagglutination inhibition and microbead array assays for the measurement of influenza antibody levels in HIV-infected adults.
Thorne A; Chowdhury F; Singer J; Keynan Y; Fowke KR; Cooper C;
Vaccine; 2016 Jun; 34(31):3584-91. PubMed ID: 27211040
[TBL] [Abstract][Full Text] [Related]
27. Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy.
Bansal R; Vergidis P; Tosh PK; Wilson J; Hathcock M; Khurana A; Bennani NN; Paludo J; Villasboas JC; Wang Y; Ansell SM; Johnston PB; Freeman C; Lin Y
Transplant Cell Ther; 2024 Apr; 30(4):455.e1-455.e7. PubMed ID: 38346643
[TBL] [Abstract][Full Text] [Related]
28. Humoral immune response following seasonal influenza vaccine in islet transplant recipients.
Silva M; Humar A; Shapiro AM; Senior P; Hoschler K; Baluch A; Wilson LE; Kumar D
Cell Transplant; 2013; 22(3):469-76. PubMed ID: 23006439
[TBL] [Abstract][Full Text] [Related]
29. Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies.
Héquet D; Pascual M; Lartey S; Pathirana RD; Bredholt G; Hoschler K; Hullin R; Meylan P; Cox RJ; Manuel O
Vaccine; 2016 Jun; 34(31):3576-83. PubMed ID: 27219339
[TBL] [Abstract][Full Text] [Related]
30. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
31. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
[TBL] [Abstract][Full Text] [Related]
32. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.
de Lavallade H; Garland P; Sekine T; Hoschler K; Marin D; Stringaris K; Loucaides E; Howe K; Szydlo R; Kanfer E; Macdonald D; Kelleher P; Cooper N; Khoder A; Gabriel IH; Milojkovic D; Pavlu J; Goldman JM; Apperley JF; Rezvani K
Haematologica; 2011 Feb; 96(2):307-14. PubMed ID: 20971824
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.
Munoz FM; Jackson LA; Swamy GK; Edwards KM; Frey SE; Stephens I; Ault K; Winokur P; Petrie CR; Wolff M; Patel SM; Keitel WA
Vaccine; 2018 Dec; 36(52):8054-8061. PubMed ID: 30416018
[TBL] [Abstract][Full Text] [Related]
35. Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects.
Liu W; Ma MJ; Tang F; He C; Zhang XA; Jiang LF; Xin DS; Hu CY; Looman C; Cao WC
Vaccine; 2012 Jul; 30(32):4785-9. PubMed ID: 22633868
[TBL] [Abstract][Full Text] [Related]
36. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection.
Hakim H; Allison KJ; Van de Velde LA; Tang L; Sun Y; Flynn PM; McCullers JA
Vaccine; 2016 Jun; 34(27):3141-3148. PubMed ID: 27129426
[TBL] [Abstract][Full Text] [Related]
38. Antibody responses induced by trivalent inactivated influenza vaccine among pregnant and non-pregnant women in Thailand: A matched cohort study.
Nakphook S; Patumanond J; Shrestha M; Prasert K; Chittaganpitch M; Mott JA; Praphasiri P
PLoS One; 2021; 16(6):e0253028. PubMed ID: 34106994
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
medRxiv; 2024 Jan; ():. PubMed ID: 38343800
[TBL] [Abstract][Full Text] [Related]
40. Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).
Kase T; Inoue M; Morikawa S; Kumashiro H; Hiroi S; Nakata K; Ito K; Ishibashi M; Tsuru T; Irie S; Maeda A; Ohfuji S; Fukushima W; Hirota Y
Vaccine; 2020 Sep; 38(42):6524-6532. PubMed ID: 32873406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
